← FDA DRUG APPROVALS

FDA ANDA · ANDA206389

BETAMETHASONE DIPROPIONATE

Sponsor: ENCUBE

APPLICATION
ANDA206389
TYPE
ANDA
ORIGINAL APPROVAL
2018-02-13
LATEST ACTION
2020-06-23
ROUTE
TOPICAL
DOSAGE FORM
LOTION, AUGMENTED
MARKETING STATUS
Prescription

Products

BETAMETHASONE DIPROPIONATEPrescription
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE · LOTION, AUGMENTED · TOPICAL

Approval history

2020-06-23Labeling · Supplement 2 · standardAP
2020-06-23Labeling · Supplement 1 · standardAP
2018-02-13UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →